Trial Profile

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS): A Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palbociclib (Primary) ; Letrozole; Tamoxifen
Indications Adenocarcinoma; Ductal carcinoma; Early breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms PELOPS

14 Jul 2023 Results assessing the effects of ET on the tumor immune microenvironment (TME) in HR+ breast cancer published in the Cancer Research
21 May 2021 Planned End Date changed from 1 Nov 2020 to 1 Apr 2031.
21 May 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Jun 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com